Biophys. 106, 234 -251), suggesting that the two inhibitors bind in a mutually exclusive fashion to pepsin. Fitting of the entire data set to the appropriate equation yielded an ␣ factor of 8 ؎ 1. The magnitude of this factor (ؕ > ␣ > 1) can be explained by a conformational distinction between the enzyme species that bind each inhibitor. The effects of pH on the inhibition constants for pepstatin A and the substituted piperidine also suggest that the inhibitors bind to distinct conformational forms of the enzyme. No inhibition by the piperidine was observed at acidic pH, while pepstatin A inhibition is maximal at low pH values. Inhibition by the piperidine was maximal when a group with pK 4.8 ؎ 0.2 was deprotonated and another group with pK 5.9 ؎ 0.2 was protonated. Most likely these two groups are the catalytic aspartates with perturbed ionization properties as a result of a significant and unique conformational change. Taken together, these data suggest that the enzyme can readily interconvert between two conformers, one capable of binding substrate and pepstatin A and the other capable of binding the substituted piperidine.
A number of aspartyl proteinases, including mammalian (renin, BACE, ␥-secretase), viral (HIV-1 1 protease) and parasitic (plasmepsin) origin enzymes have been identified as useful targets for chemotherapeutic intervention (1) (2) (3) (4) . A significant number of peptidomimetic inhibitors, designed as stable bisubstrate analogues (with statine, hydroxyethylene, or fluorostatone isosteres), have been developed. Some of these have even reached clinical trials, but were abandoned later due to a limited bioavailability or excessive production costs. New structural classes of nonpeptidic inhibitors, with improved physicochemical properties, were identified (5-9) through screening or rational design techniques for a number of therapeutically important aspartyl proteases. Three-dimensional crystal structures of some of these inhibitors bound to their target enzymes have been reported (5, 6) , and this has aided lead optimization with respect to selectivity and affinity. However, attainment of structural information is not always straightforward. In these cases the inhibitor modality and binding site have to be inferred from kinetic analysis of enzyme inhibition.
Peptidic inhibitors with tetrahedral intermediate isosteres usually bind to aspartyl proteases in an extended conformation with the pro-S C-3 hydroxyl group displacing the catalytic water and hydrogen bonding to the catalytically essential aspartates (10) . These inhibitors usually are competitive with respect to the substrate peptide (11, 12) , and if the amino acid sequence of the natural peptidic substrate is available, optimization of such inhibitors is straightforward. The situation is more complex for non-peptidic inhibitors, where a significant distortion of the enzyme active center is observed upon inhibitor binding (13) . These dramatic structural changes are difficult to predict, hence rational optimization of inhibitors is precluded in the absence of structural information.
Recently a series of 4Ј-substituted piperidines has been identified as potent renin (14) , plasmepsin (13) , and pepsin (15) inhibitors. A renin crystal structure with a potent piperidine bound indicates significant conformational shift (opening) of the flap and relocation of the Trp39 side chain to accommodate the 4Ј substituent (13) . The protonated nitrogen of the piperidine moiety is positioned between the two catalytic aspartates making two strong hydrogen bonds. These compounds are potent inhibitors of renin in vitro (subnanomolar IC 50 values) and show blood pressure decreasing activity in sodium-depleted marmosets (6) . Substituted piperidines are also active against parasitic aspartyl proteases and display activity against malaria in cell culture (16) .
Attempts to model piperidines in the porcine pepsin active site suggested that it is possible to design piperidine-based inhibitors for a number of aspartyl proteases, assuming that most of these enzymes can adopt conformations similar to renin (15) . However, no direct structural or kinetic evidence has been presented to address the nature of the interactions between these inhibitors and aspartyl proteases in solution. Also, the physicochemical properties of these compounds (e.g. poor aque-ous solubility and the potential to form aggregate structures in solution) can lead to general nonspecific inhibition of some aspartyl proteases at high inhibitor concentrations. 2 Hence, it is important to establish the mode of specific inhibition of aspartyl proteases by these compounds through solution-phase kinetic and equilibrium methods. In this study we sought to fill this void by studying the interactions of a 4Ј-substituted piperidine with the aspartyl protease porcine pepsin. Using a combination of steady-state kinetics and pre-equilibrium binding methods we show here that the substituted piperidines are active site-directed inhibitors that may bind to an enzyme conformer that is distinct from the enzyme form that binds substrate and more traditional peptide-tetrahedral isostere inhibitors.
EXPERIMENTAL PROCEDURES
Synthesis of the Substituted Piperidine and Rhodamine Green-modified Peptide Inhibitor-The rhodamine green-labeled statine inhibitor was synthesized using a 2-chlorotrityl chloride solid support and utilizing standard O-azabenzotriazol-1-yl)-N,N,NЈ,NЈ-tetramethyluronium hexafluorophosphate (HATU) coupling conditions. The inhibitor was cleaved from the solid support, dissolved in a 0.1 M sodium bicarbonate buffer, and labeled with rhodamine green succinimidyl ester (Molecular Probes) in N,N-dimethylformamide. The labeled peptide was purified by reverse-phase HPLC and lyophilized to dryness.
The substituted piperidine inhibitor was prepared in a manner similar to that previously reported (15, 17) . Briefly, triisopropylsilyl-protected 4-hydroxyphenylmagensium bromide was added to t-butoxycarbonyl-protected 4-piperidone. The resulting carbinol was eliminated with phosphorus oxychloride in pyridine, and the olefin was converted to the (S,S)-diol using the Sharpless asymmetric dihydroxylation. The benzylic tertiary alcohol was then removed using Raney nickel, and the triisopropyl silyl group was cleaved with tetrabutylammmonium fluoride and replaced with an allyl ether using potassium carbonate and allyl bromide to provide the protected (R,R)-diol. The 2-naphthylmethyl ether was then introduced by alkylation with the corresponding alkyl bromide and potassium tert-butoxide, the allyl ether was removed using tetrakis (triphenylphosphine) palladium (0), and the remaining ether group was introduced by alkylation using potassium carbonate and bromomethyl-2-napthyl ketone.
Steady-state Kinetic Assays-Porcine pepsin (Sigma) activity was measured under steady-state conditions following fluorescence signal increase (excitation at 340 nm, emission at 490 nm) upon the cleavage of the Ac-ED(EDANS)KPILFFRLGK(DABCYL)E-NH 2 substrate (Bachem). Assays were performed in 96-well plates using a SPECTRAmax GEMINI XS (Molecular Devices) microplate spectrofluorometer. Typically, 0.1 ml of 50 mM acetate buffer, pH 5.0 or 3.0, containing 40 nM pepsin was mixed with 0.004 ml of inhibitor in Me 2 SO (final Me 2 SO concentration in the assay was 2%), and the reaction was initiated by the addition of 0.1 ml of 0.02 mM substrate in the same buffer (final concentration of enzyme was 20 nM and substrate 0.01 mM). Mutual exclusivity and HPLC experiments contained 0.6 nM enzyme. Enzyme concentration was determined from the absorbance at 278 nm (⑀ 278 ϭ 51,000 M Ϫ1 cm Ϫ1 ) and reconfirmed by active site titration with pepstatin A (Sigma) as a tight binding inhibitor
Inhibitor potency was evaluated by fitting inhibition data to the binding isotherm,
where v is the reaction velocity at different concentrations of inhibitor I; v 0 is the control velocity in the absence of inhibitor; and n is the number of the inhibitor molecules bound to the enzyme.
Inhibitor modality under steady-state conditions was determined by measuring the effect of inhibitor concentration on initial velocity as a function of substrate concentration. Data were fit globally to the following equation for competitive inhibition (18) .
Mutual exclusivity studies were performed at one fixed substrate concentration varying pepstatin A and piperidine concentrations, and data were evaluated according to Ref. 19 .
Alternatively, an HPLC assay was used to determine kinetic parameters and inhibition under different pH conditions. For this assay 0.2-ml reactions were set up in Eppendorf tubes (identical conditions as the fluorescence assay). After 5 min the reaction was stopped by boiling, and the mixture was injected onto a C18 reverse-phase HPLC column (Waters). Reaction products were eluted with a linear 0 -80% acetonitrile gradient monitoring absorbance at 490 nm. The kinetic parameters, V and K m , as well as K i , were measured at different pH values using 50 mM citrate, pH 2.0 -4.0, and 50 mM acetate, pH 4.0 -6.0, buffers. Data for the pH profiles, which go from a slope 0 to Ϫ1 at higher pH values, were fit to Equation 4 .
Bell-shaped pH profile was fit to Equation 5 .
In both equations y is the experimental value of the parameter, C is a pH-independent value, and K is the dissociation constant for the ionizable group. Stopped-flow Experiments-Pre-equilibrium binding studies were conducted using an Applied Photophysics SX.18MV stopped-flow fluorometer (Leatherhead, UK). Experiments were performed by rapid mixing of equal volumes of the reagents in 50 mM acetate buffer, pH 5.0, at 15°C. The complex of pepsin (0.5 M) and rhodamine green-modified statine inhibitor (rg-E-V-N-benzA-stat-A-E-F-OH, 5 M) was mixed in the stopped-flow chamber with pepstatin A (2 M) or piperidine (20 M). The excitation wavelength was set at 295 nm, and fluorescence was followed using a narrow band filter (545 Ϯ 10 nm, Melles Griot). Data were collected for 10 s, and traces were fit to a single exponential equation to obtain k obs . Data were reproducible despite a low signal to noise ratio. For each experiment about 5-10 transients were averaged. The instrument dead time was 1.2 ms. Simulations were performed using KINSIM and FITSIM software. Initially, fitting was optimized by incremental adjustment of individual rate constants by visual inspection of the generated theoretical curve with the experimental data using KINSIM. Once a reasonable fit was obtained, final parameter calculation was made by the use of the program FITSIM.
RESULTS

Steady-state Inhibition and pH
Profiles-Pepsin demonstrates maximal enzymatic activity near pH 3.0 (20) . At this pH the enzyme is potently inhibited by pepstatin A. The substituted piperidine (Fig. 1) , however, is ineffective as a pepsin inhibitor at this pH. The pH profile for the kinetic parameter V/K of pepsin was measured from pH 2 to 6 ( Fig.  2A) . The data display a single titration that is well fit by Equation 4 to yield a pK value of 5.1 Ϯ 0.3. These data are in good agreement with previous studies reported in the literature (21) . A second titration with a pK of 1.5 (a feature associated with the general-base aspartate) is not obvious from our experiments, since we did not extend the pH range low enough. The pH profile for inhibition of pepsin by pepstatin A displays a remarkably similar titration curve (Fig.  2B ) with a pK value of 5.6 Ϯ 0.1. In stark contrast to the above results, the pH profile for inhibition of pepsin by the substituted piperidine (Fig. 2C) displays a maximum at pH 5.0 and appears to involve two distinct titration events in the same pH range. Fitting the data to Equation 5 revealed two ionizable groups involved in piperidine binding. Inhibition by the substituted piperidine is maximal when a group with pK ϭ 4.8 Ϯ 0.2 is deprotonated and another group with pK ϭ 5.9 Ϯ 0.2 is protonated. Attempts to alternatively fit these data to one titration event, with maximal inhibition requiring deprotonation of a single group, were unsatisfactory. All subsequent experiments were performed at pH 5.0.
Evaluating the potency of the substituted piperidine in pepsin assays we noticed that the IC 50, defined by Equation 1, increased linearly with increasing substrate concentration (data not shown), suggesting that this inhibitor competes for the substrate binding site (22) . To verify this interpretation, the velocity of the enzymatic reaction was evaluated with systematic variations in substrate and inhibitor concentration. These data were fit globally to the steady-state equation for competitive inhibition (Equation 2) and yielded a calculated value of K i of 3.2 Ϯ 1.5 M (Fig. 3A) . The competitive nature of this inhibition was further confirmed by fitting the data for each inhibitor concentration in Fig. 3A individually to the Michaelis-Menten equation and thus deriving apparent values of K m and V max . As illustrated in Fig. 3B , the apparent K m value increased linearly with increasing inhibitor concentration, while the value of V max was unaffected by the presence of inhibitor; this pattern is consistent with competitive inhibition (23) .
Mutual Exclusivity Studies-To confirm further the hypothesis that the piperidine derivative is binding by engaging the active site aspartates, we performed mutual exclusivity studies. Pepstatin A, a naturally occurring peptidic inhibitor containing the statine isostere, is known to bind aspartyl proteases at their active sites, with the hydroxyl of the statine moiety hydrogen bonding to the catalytic aspartates (24). Therefore, if the substituted piperidine is binding at the active site, a mutual exclusivity pattern should be observed when these two inhibitors are varied at one fixed concentration of the substrate. Yonetani-Theorell plots (19) (Fig. 4) constructed from the data obtained by varying the piperidine concentration at different fixed concentrations of pepstatin A showed parallel lines. Fitting these data to Equation 3 yielded K i values of 2.1 Ϯ 0.2 nM and 1.5 Ϯ 0.1 M for pepstatin A and the piperidine, respectively, and an interaction coefficient ␣ of 8 Ϯ 0.9. This latter value, ϱ Ͼ ␣ Ͼ 1, is indicative of negative interactions between the binding of the two inhibitors, but requires a more complex mechanism than simple competition for a common enzyme species. Yonetani and Theorell (19) suggest several potential explanations for such a value of ␣; these include ion-dipole interactions, hydrophobic or hydrophilic interactions, and protein conformational changes involved in differential inhibitor binding (19) .
Pre-equilibrium Binding-The rhodamine green (rg) dyemodified statine inhibitor displays a strong fluorescence signal at 530 nm when excited at 295 nm (Fig. 5, trace 1) . This fluorescence is modestly enhanced when the inhibitor binds to pepsin (Fig. 5, trace 2) under equilibrium binding conditions. Under the same conditions the enzyme's tryptophan fluorescence at 340 nm is quenched (Fig. 5, inset trace 2) , most likely as a result of the spectroscopic properties of the dye (absorbance at 340 nm) in solution. Although the magnitude of the signal change is small, the change in signal at 530 -550 nm is unique to the inhibitor-pepsin complex and thus provides a convenient means of following complex formation and dissociation. We therefore used this signal to assess the ability of the substituted piperidine to displace the fluorescent peptide inhibitor from pepsin under pre-equilibrium conditions. When the preformed rg-peptide⅐pepsin complex (0.5 and 5 M, respectively) was mixed with an equal volume of 20 M substituted piperidine, a time-dependent diminution of fluorescence signal was observed which could be fit to a first order decay curve with k obs ϭ 0.4 Ϯ 0.1 s Ϫ1 (Fig. 6) . A similar decay of fluorescence intensity was observed when the preformed rg-peptide⅐pepsin complex was mixed with an equal volume of 2 M pepstatin A (data not shown), indicating that both pepstatin A and the substituted piperidine were similarly capable of displacing the rg-modified peptide from pepsin.
DISCUSSION
Conformational adjustments in enzyme active sites are common features of the reaction pathways for many enzymes. Conformational changes have been experimentally observed to attend binding of substrates, reaction intermediates, and inhibitor molecules to enzymes. A number of aspartyl proteases have been reported to undergo "flap" closing when bisubstrate analogues (peptide with statine or hydroxyethylene isosteres) occupy the substrate binding site (25, 26) . Established hydrogen bonds between the residues within the flap and complementary carbonyl oxygens and amide protons of the peptide serve to align the scissile peptide sequence in the protease active site. These peptidomimetic inhibitors usually show slow binding behavior, which could be attributed to tightening of the enzyme-inhibitor complex as a result of flap closing. Totally different conformational changes have been observed in the three-dimensional structure of the renin active site upon non-peptidic inhibitor binding (13) . This novel binding pattern bares little resemblance to the ex- tended ␤-sheet structure of the substrate, but nevertheless renders potent inhibition of the enzyme. Our present study of pepsin inhibition by a substituted piperidine (Fig. 1 ) revealed several unique features as well. Aspartyl protease-catalyzed peptide cleavage involves a general-acid, general-base chemical mechanism in which two active site aspartates are in opposite states of protonation (27) . This is generally reflected in bell-shaped pH profiles for the free enzyme (log V/K) and for the enzyme-substrate complex (log V). We reconfirmed that pepsin cleaves the peptide substrate used in this study by the same chemical mechanism, and the pK of 5.1 (for the general-acid aspartate) determined here for the free enzyme is in a good agreement with the value reported earlier (21) . The general-base aspartate pK is not reflected in the Fig. 2A pH profile, since experimental conditions were not extended to low enough pH. A similar pH profile was observed for the inhibition by pepstatin A (Fig. 2B) , reconfirming that the enzyme-inhibitor complex is similar to the enzyme-substrate complex, and that pepstatin A binds to the monoprotonated form of the proteases, as has also been demonstrated by 13 C NMR (28, 29) , neutron Laue diffraction (30) , and isothermal titration calorimetry (31) methods.
A very different pH profile was observed for the piperidine pK i (Fig. 2C) , suggesting either that other ionizable groups are critical for piperidine binding or that the pK values of the catalytic aspartates are significantly perturbed. A similar decrease in affinity at acidic pH was observed in the binding of a cationic inhibitor to HIV protease (32) . This observation was interpreted as evidence that the cationic inhibitor binds exclusively to the unprotonated enzyme, forming an ionic bond to Asp-25Ј, which is normally protonated in the catalytically competent enzyme. An alternative explanation for these results would be a large shift of both aspartate pK values as a result of a significant conformational change. Our data suggest that the substituted piperidines most likely bind to a monoprotonated form of the enzyme (indicated by the bell-shaped pH dependence) in which the pK of both aspartates is perturbed. We cannot exclude the alternative possibility that the piperidine inhibition pH profile reflects ionization of critical groups other than the active site aspartates, although the demonstration of competitive inhibition by the piperidine (Fig. 3) and the known interactions of these inhibitors with the active site aspartates of renin (13) make this alternative explanation less likely.
Substituted piperidine binding in the active site of pepsin is evident from the combined data of steady-state inhibition and pre-equilibrium binding studies. Even though drastic structural rearrangements were observed upon piperidine binding in the case of renin, we did not notice any time dependence of the pepsin inhibition. It has been suggested previously that peptidomimetic inhibitors and piperidines bind to the dynamic ensemble of pre-existing enzyme conformations, stabilizing the geometry of the binding site (15) . Our data indicate that two conformers of pepsin (one binding statines and the other binding piperidines) are in rapid equilibrium and can be stabilized by appropriate inhibitors. The energy barrier for interconversion between these two conformers cannot be significant, as our data suggest facile competition between the statines and the piperidine (see Figs. 4 and 6) .
To further address interconversion between these proposed conformers we performed displacement experiments under pre-equilibrium conditions. The preformed complex of pepsin and rhodamine green-modified statine inhibitor (E-rgStat) was mixed in a stopped-flow chamber with an excess of piperidine (Pip). The molecular processes that attend interactions between pepsin and these inhibitors can be described by either of the following two kinetic schemes.
We do not have any independent evidence of the exact path of E and EЈ interconversion (i.e. does it occur at the level of the free enzyme or subsequent to inhibitor binding), since no biphasic behavior was observed in the overall process, even on a stopped-flow time scale. Nevertheless our pH and mutual exclusivity data clearly point out that different final conformations are stabilized by the piperidine and statine inhibitors.
The E-rgStat complex has an increased fluorescence signal (compared with free rgStat, Fig. 5 ) as a result of energy transfer from pepsin tryptophans to the dye; the diminution of this signal upon mixing with the piperidine (under pre-equilibrium conditions) indicated formation of an EЈ-Pip complex. The rate constant for the overall displacement reaction was independent of enzyme, rgStat, or Pip concentrations, and thus k 1 
Under these conditions the measured k obs is equivalent to the dissociation rate constant k Ϫ1 (33) . Simulation of the reaction course (FITSIM software) using data from The monophasic nature of these displacement time courses and the excellent agreement between the dissociation constants measured by this method and by independent experiments indicate that the interconversion between conformers E and EЈ does not impart a rate limitation to the kinetics of ligand exchange for pepsin. This suggests that despite the stabilization of each conformer by one or the other inhibitor, the enzyme can nevertheless undergo rearrangements of the active site to adopt the alternative conformation rapidly upon ligand binding/dissociation.
The catalytic competence of these two conformers could be interpreted in terms of an iso uni-bi kinetic mechanism, which has been proposed for HIV protease (32) and pepsin (34) . According to this mechanism the enzyme is challenged to adopt more than two conformations, differing in geometry, protonation state, and proton localization (34) during catalytic turnover. We do not have enough evidence to define the nature of the conformer that binds the substituted piperidine, but a more complete understanding of these interconverting conformational states of the enzyme may help to define novel mechanisms for aspartyl protease inhibition. This may also serve to define limitations for specific inhibitor classes (e.g. the piperidines) under physiologically relevant pH conditions.
